Research Progress of Comprehensive Utilization of Plasma in China

doi:10.3969/j.issn.1671-2587.2022.06.024

JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE ›› 2022, Vol. 24 ›› Issue (6): 807-816.DOI: 10.3969/j.issn.1671-2587.2022.06.024

Research Progress of Comprehensive Utilization of Plasma in China

PEI Ren-jun, FEI Zhang-cheng, PAN Bo, et al

Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu 610052

Received:2022-09-23 Published:2023-01-05

Abstract

Abstract: With the increasing aging of Chinese population in the coming decades, plasma collection will have a huge impact. How to improve the comprehensive utilization of plasma is an urgent problem to be solved in the industry. In this paper, the collection of raw plasma, the types and preparation process of plasma protein products, the research status of plasma protein, and the regulations to promote the comprehensive utilization of plasma were reviewed. At present, the types of plasma protein products in China are increasing, and relevant policies to promote the comprehensive utilization of plasma are constantly introduced. However, compared with foreign countries, China manufacturers are small in scale, lack of motivation for research and development of new products and new technologies, and lack of in-depth research on plasma protein products. The merger and acquisition of plasma protein products enterprises, the strengthening of industry-university-research cooperation, and the improvement of scientific research strength will be the direction of future development.

Key words: Plasma, Comprehensive utilization, Plasma protein products, Separation and purification, Virus inactivation/removal

CLC Number:

R977.8

PEI Ren-jun, FEI Zhang-cheng, PAN Bo, et al. Research Progress of Comprehensive Utilization of Plasma in China[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(6): 807-816.

References

[1] 王娅,李长清,刘忠.我国血站富余分离血浆用于血液制品生产的思考[J]. 中国输血杂志,2015,28(5):585-587.
[2] 国家统计局.第七次全国人口普查公报(第五号)[EB/OL].(2021-05-11). http://www.stats.gov.cn/tjsj/tjgb/rkpcgb/qgrkpcgb/202106/t20210628_1818824.html.
[3] 国家卫生健康委员会. 国家卫生健康委办公厅关于印发献血浆者须知(2021年版)的通知[EB/OL].(2021-09-09).http://www.nhc.gov.cn/yzygj/s7658/202109/ca7e7e1972ec4e939c613aa67f7434e1.shtml.
[4] 卫生健康委.单采血浆站管理办法[EB/OL].(2008-01-04). http://www.gov.cn/flfg/2008-02/29/content_905730.htm.
[5] 中华人民共和国国务院.血液制品管理条例[EB/OL].(2016-02-06). http://www.gov.cn/zhengce/2020-12/26/content_5574888.htm.
[6] 国家药品监督管理局.生物制品批签发管理办[EB/OL].(2020-12-11).http://www.gov.cn/gongbao/content/2021/content_5588831.htm.
[7] 中华人民共和国卫生部.药品生产质量管理规范(2010年修订)[EB/OL].(2011-01-17).https://www.nmpa.gov.cn/xxgk/fgwj/bmgzh/20110117120001434.html.
[8] 国家食品药品监督管理局办公室.关于实施血液制品生产用原料血浆检疫期的通知[EB/OL].(2007-07-18). https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20070718010101836.html.
[9] 国家食品药品监督管理局办公室.实施原料血浆检测管理技术指导原则[EB/OL].(2008-08-20). https://www.militu.com/p-5395398.html.
[10] 杨敬鹏,徐晓楠.血液制品生产用血浆国内外监管的异同[J]. 中国药事,2019,33(7):732-736.
[11] 王卓,赵雄,吕茂民,等.血液制品的现状与展望[J].生物工程学报,2011,27(5):730-746.
[12] 陈奋则,丁玉江,张信,等.国内外原料血浆综合利用水平的比较[J]. 微生物学免疫学进展,2010,38(3):67-73.
[13] KISTLER P,NITSCHMANN H.Large scale production of human plasma fractions. Eight years experience with the alcohol fractionation procedure of Nitschmann,Kistler and Lergier[J]. Vox Sang,1962,7:414-424.
[14] BURNOUF T.Modern plasma fractionation[J].Transfus Med Rev,2007,21(2):101-117.
[15] 杨成民,刘进,赵桐茂,等.中华输血学[M].第一版.北京:人民卫生出版社.2017:301.
[16] 刘颖. 人血白蛋白制剂中蛋白组分的研究[D].武汉:湖北中医药大学,2017.
[17] 赵嘉和,张洁明,裴成斌.低温乙醇蛋白分离压滤法技术的应用效果[J]. 中国输血杂志,2001,14(5):289-290.
[18] 杨汇川,孟丽,林晓军,等.人血白蛋白制备中铝离子含量的控制[J]. 中国输血杂志,2000,13(4):239-241.
[19] 肖林,郝杰,程雅琴,吕秀华.人血白蛋白制品浊度与稳定性的分析[J]. 中国生物制品学杂志,2002,15(6):366-368.
[20] 喇文军,王妍,周靖,等. 一步柱层析纯化血浆分离多种血液制品组分[J]. 中国生物制品学杂志,2015,28(2):194-198.
[21] RAOUFINIA R,BALKANI S,KEYHANVAR N,et al.Human albumin purification:a modified and concise method[J].J Immunoassay Immunochem,2018,39(6):687-695.
[22] MCCANN K B,VAN ALSTINE J,MARTINEZ J,et al.Polyacrylic acid based plasma fractionation for the production of albumin and IgG:compatibility with existing commercial downstream processes[J]. Biotechnol Bioeng,2020,117(4):1072-1081.
[23] MOUSAVI HOSSEINI K,GHASEMZADEH M.Implementation of plasma fractionation in biological medicines production[J]. Iran J Biotechnol,2016,14(4):213-220.
[24] 邱苏赣,贾东晨. 2013—2017年间我国进口人血白蛋白概况[J]. 中国生物制品学杂志,2018,31(8):923-928.
[25] 林孝发,王妍. 层析技术在血液制品分离纯化中应用的探讨[J]. 微生物学免疫学进展,2015,43(1):73-78.
[26] 刘敏亮,杨笃才,阮景文,等.一种新的静注人免疫球蛋白制剂制备工艺的研究[J].中南药学,2015,13(4):376-378.
[27] 张学成,马小伟,安文琪,等.阴离子交换层析处理对静注人免疫球蛋白(pH 4)制品的影响[J].中国生物制品学杂志,2019,32(9):1036-1042.
[28] 邹炜,李策生,周志军,等.层析法从血浆分离静注人免疫球蛋白及其初步检定[J].微生物学免疫学进展,2013,41(5):10-13.
[29] BRESOLIN I T L,DE SOUZA M C M,BUENO S M A.A new process of IgG purification by negative chromatography:adsorption aspects of human serum proteins onto Omega-aminodecyl-agarose[J]. J Chromatogr B Analyt Technol Biomed Life Sci,2010,878(23):2087-2093.
[30] 蒋徳席,刘文芳.世界血浆蛋白制品的市场与前景[J].中国输血杂志,2008,21(11):903-905.
[31] RADOSEVICH M,BURNOUF T.Intravenous immunoglobulin G:trends in production methods,quality control and quality assurance[J].Vox Sang,2010,98(1):12-28.
[32] RADOMSKI K U,LATTNER G,SCHMIDT T,et al.Pathogen safety of a new intravenous immune globulin 10% liquid[J].BioDrugs,2017,31(2):125-134.
[33] LAURSEN I A,BLOU L,SULLIVAN J S,et al.Development,manufacturing and characterization of a highly purified,liquid immunoglobulin g preparation from human plasma[J]. Transfus Med Hemother,2014,41(3):205-212.
[34] VELTHOVE K J,OVER J,ABBINK K,et al.Viral safety of human plasma-derived medicinal products:impact of regulation requirements[J]. Transfus Med Rev,2013,27(3):179-183.
[35] 梁婧,张潇文,李策生,等.低pH孵放病毒灭活效果回顾性验证评价[J]. 中国输血杂志,2016,29(9):915-917.
[36] EL-EKIABY M,VARGAS M,SAYED M,et al.Minipool caprylic acid fractionation of plasma using disposable equipment:a practical method to enhance immunoglobulin supply in developing countries[J]. PLoS Negl Trop Dis,2015,9(2):e0003501.
[37] KORNEYEVA M,HOTTA J,LEBING W,et al.Enveloped virus inactivation by caprylate:a robust alternative to solvent-detergent treatment in plasma derived intermediates[J]. Biologicals,2002,30(2):153-162.
[38] 张宝献,张剑涛,刘亚芳,等.纳米膜过滤和低pH孵放法去除/灭活静注人免疫球蛋白中病毒效果的验证[J]. 国际生物制品学杂志,2021,44(1):44-47.
[39] 张庭喜,孔维权,王连群,等.一种从Cohn组分I沉淀分离纤维蛋白原的方法:CN104387466A[P].2015-03-04.
[40] 谢来峰,孙培森,张学成,等.一种人纤维蛋白原的制备方法:CN113754757A[P].2018-06-22.
[41] 刘敏亮,梁小明,罗二华,等.一种高浓度人纤维蛋白原的制备工艺:CN111560064A[P]. 20200821.
[42] GILBERT A,EVTUSHENKO M,NAIR H.Purification of fibrinogen and virus removal using preparative electrophoresis[J].Ann N Y Acad Sci,2001,936:625-629.
[43] 赵雄,尹惠琼,章金刚.纤维蛋白原制品病毒灭活方法研究进展[J]. 中国输血杂志,2008,21(2):141-144.
[44] DOLIA S,VERMA S,PAWAR A,et al.Quality attributes of plasma derived human fibrinogen (fibrogen-I®)[J]. Plasmatology, 2021.
[45] SCHULZ P M,GEHRINGER W,NÖHRING S,et al. Biochemical characterization,stability,and pathogen safety of a new fibrinogen concentrate (fibryga®)[J]. Biologicals,2018,52:72-77.
[46] 李青,刘晓,文圆,等.人凝血因子Ⅷ工艺过程效价检测与分析[J]. 中国生物制品学杂志,2017,30(2):186-191.
[47] 菅长永. 人凝血因子Ⅷ分离纯化工艺研究[D].济南:山东大学,2012.
[48] 康丽梅,张焱,罗坚,等.超大孔离子交换制备色谱分离纯化高活性凝血因子Ⅷ[J]. 色谱,2012,30(6):618-623.
[49] BURNOUF T,BURNOUF-RADOSEVICH M,HUART J J,et al.A highly purified factor Ⅷ:c concentrate prepared from cryoprecipitate by ion-exchange chromatography[J]. Vox Sang,1991,60(1):8-15.
[50] MORFINI M,COPPOLA A,FRANCHINI M,et al.Clinical use of factor Ⅷ and factor IX concentrates[J]. Blood Transfus,2013,11(Suppl 4):s55-s63.
[51] FURUYA K,MURAI K,YOKOYAMA T,et al.Implementation of a 20-nm pore-size filter in the plasma-derived factor Ⅷ manufacturing process[J]. Vox Sang,2006,91(2):119-125.
[52] 周敏,曾仁勇,刘园园,等.新型凝胶纯化凝血酶原复合物的工艺探讨[J].中国生化药物杂志,2016,36(11):192-196.
[53] CAO H J,LI C Q,HUANG Y,et al.Influence of washing conditions on effective components of prothrombin complex concentrates[J].Prep Biochem Biotechnol,2014,44(2):164-181.
[54] 曹海军,李志雄,叶生亮,等.洗脱条件及其因素对凝血酶原复合物有效成分的影响[J].中国输血杂志,2013,26(4):349-353.
[55] 曹海军,王宗奎,胡吉军,等.不同吸附体系及因素水平对PCC中4类抗凝蛋白的影响研究[J].中国输血杂志,2012,25(12):1283-1287.
[56] 刘欣晏,王凤山,仲立军,等.采用两步凝胶吸附法制备人凝血酶原复合物的工艺研究[J].中国生化药物杂志,2008,28(1):26-29.
[57] MCCANN K B,GOMME P T,WU J,et al.Evaluation of expanded bed adsorption chromatography for extraction of prothrombin complex from Cohn Supernatant I[J]. Biologicals,2008,36(4):227-233.
[58] 黄亮,赵红卫,李长清,等.新型树脂扩张床吸附分离PCC的工艺及其放大研究[J].中国输血杂志,2011,24(6):485-488.
[59] 庾昌文,何甜,王振国,等.一种高纯人凝血酶的制备方法:CN113652414A[P].2021-11-16.
[60] BOCTOR A,MEHTA S,RADEBAUGH G.Ultra-pure thrombin preparation:US5397704[P].1995-03-14.
[61] AIZAWA P,WINGE S,KARLSSON G.Large-scale preparation of thrombin from human plasma[J]. Thromb Res,2008,122(4):560-567.
[62] 匡青芬,陈新朋,杨笃才,等.高纯度凝血因子Ⅸ制剂的制备方法[J].临床医药实践,2016,25(6):452-455.
[63] 胡川,罗观文,李文善,等.响应面法优化人凝血因子Ⅸ肝素亲和层析条件研究[J].中国输血杂志,2021,34(1):26-29.
[64] 朱光祖,罗观文,胡川,等.一种高纯人凝血因子Ⅸ制剂的生产方法:CN110257358A[P]. 20190920.
[65] BEGIĆ M,PEČENKOVIĆ S,GAJDOŠIK M Š,et al. Salt-tolerant cation exchanger-containing sulfate groups as a viable alternative for mixed-mode type and heparin-based affinity resins[J]. Biotechnol J,2021,16(11):2100100.
[66] ADHIKARI S,NICE E C,DEUTSCH E W,et al.A high-stringency blueprint of the human proteome[J]. Nat Commun,2020,11(1):5301.
[67] KEATING S M,MIZRAHI R A,ADAMS M S,et al.Generation of recombinant hyperimmune globulins from diverse B-cell repertoires[J]. Nat Biotechnol,2021,39(8):989-999.
[68] HALPERT G,KATZ I,SHOVMAN O,et al.IVIG ameliorate inflammation in collagen-induced arthritis:projection for IVIG therapy in rheumatoid arthritis[J]. Clin Exp Immunol,2021,203(3):400-408.
[69] GUPTA S,PATTANAIK D,KRISHNASWAMY G.Common variable immune deficiency and associated complications[J]. Chest,2019,156(3):579-593.
[70] DODEL R,HAMPEL H,DEPBOYLU C,et al.Human antibodies against amyloid beta peptide:a potential treatment for Alzheimer's disease[J]. Ann Neurol,2002,52(2):253-256.
[71] 费章城,陈钟声,裴仁俊,等.不同β-淀粉样蛋白抗体含量的IVIG对阿尔茨海默病模型小鼠认知功能干预效果初探[J]. 中国输血杂志,2022,35(7):683-689.
[72] WANG T,XIE X X,JI M,et al.Naturally occurring autoantibodies against Aβ oligomers exhibited more beneficial effects in the treatment of mouse model of Alzheimer's disease than intravenous immunoglobulin[J]. Neuropharmacology,2016,105:561-576.
[73] 菅长永,董方玉,陈晨,等.中国血浆蛋白制品的展望[J]. 中国输血杂志,2022,35(2):227-232.
[74] 格隆汇.博雅生物(300294.SZ):人血管性血友病因子获批临床[EB/OL].(2021-08-06) https://www.gelonghui.com/news/595445.
[75] 智药数据.组织纤溶酶原激活剂治疗视网膜下出血的临床研究[EB/OL].(2020-12-31).https://db.yaozh.com/linchuangshiyan?comprehensivesearchcontent=%E7%BA%A4%E6%BA%B6%E9%85%B6%E5%8E%9F&.
[76] 吕献忠,孔冬冬.抗D人免疫球蛋白的制备方法: CN102816237A[P].2012.
[77] 中华人民共和国卫生部.卫生部关于禁止进口Ⅷ因子制剂等血液制品的通告[EB/OL].(1986-01-29). http://www.lscps.gov.cn/html/19708.
[78] 王燕波,孙钟毓,李杰,等.我国血液制品生产监管法律法规历史沿革及发展建议[J].食品与药品,2017,19(6):459-465.
[79] 国务院办公厅.国务院办公厅关于印发中国遏制与防治艾滋病行动计划(2001 —2005年)的通知[EB/OL]. (2001-05-25). http://www.gov.cn/gongbao/content/2001/content_60908.htm.
[80] 中华人民共和国卫生部. 关于单采血浆站管理有关事项的通知[EB/OL].(2012-01-20). http://www.gov.cn/gzdt/2012-01/20/content_2050385.htm.
[81] 医政医管局.关于促进单采血浆站健康发展的意见[EB/OL].(2016-12-15)http://www.nhc.gov.cn/yzygj/s3590/201612/6a508ca0df3d43428a3cb6419afb89d8.shtml.
[82] 卫生健康委、民政部、医保局、中医药局、药监局. 关于开展儿童血液病、恶性肿瘤医疗救治及保障管理工作的通知[EB/OL].(2019-07-30). http://www.gov.cn/zhengce/zhengceku/2019-11/18/content_5453137.htm.
[83] 国家药典委员会. 中华人民共和国药典临床用药须知[M]. 2015年版.北京:中国医药科技出版社,2017.
[84] AAGAARD L,KRISTENSEN K.Off-label and unlicensed prescribing in Europe:implications for patients' informed consent and liability[J]. Int J Clin Pharm,2018,40(3):509-512.
[85] 纪键. 工艺和研究实力决定未来血液制品竞争格局[J]. 现代商业银行,2021(3):76-81.
[86] LÜNEMANN J D,NIMMERJAHN F,DALAKAS M C. Intravenous immunoglobulin in neurology—mode of action and clinical efficacy[J]. Nat Rev Neurol,2015,11(2):80-89.
[87] KLAVER A C,FINKE J M,DIGAMBARANATH J,et al.Antibody concentrations to Abeta1-42 monomer and soluble oligomers in untreated and antibody-antigen-dissociated intravenous immunoglobulin preparations[J]. Int Immunopharmacol,2010,10(1):115-119.
[88] 中国食品药品检定研究院.2017年生物制品批签发年报[R]. 2017.
[89] 陈玉琴,叶苗,侯继锋.血液制品“十二五”期间倍增计划可行性分析与策略探讨[J]. 中国药事,2014,28(1):26-29.

Research Progress of Comprehensive Utilization of Plasma in China

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

About

Author

Journal

Access Statistics

Contact

[1]	MAO Ping-ping, WANG Shu-jun, LUO Kai-yun, et al. Study on the Antibacterial Effect of Frozen Platelet-rich Plasma and Lyophilized Platelet-rich Plasma [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(6): 705-709.
[2]	WEI Yan, LIU Kuan, LI Xiang-jun, et al. Observation on the Therapeutic Effect of PRP in the Treatment of Traumatic Synovitis of Ankle Joint [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(6): 725-729.
[3]	HU Qiu-yue, XU Shou-guang, ZHOU Yuan, et al. Organization and Management of Collection and Supply for COVID-19 Convalescent Plasma in Some Provinces and Cities in China [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(3): 291-296.
[4]	ZHANG Li-bo, HUANG Hui-qing, ZHAO Guo-qing, et al. Analysis of Recruitment and Demography of COVID-19 Convalescent Plasma Donors [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(3): 297-301.
[5]	MI Wen-jing, LI Li-wei, LI Xing-long, et al. A Comparative Study of TRALI Rat Model Induced by Human Plasma and Homo/Heterologous Rat Plasma [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(2): 193-196.
[6]	LIU Ye, MAO Jia-xi, LIU Cong, et al. Efficacy Analysis of Plasma Exchange on Patients with Hepatitis B Associated Chronic Acute Liver Failure Awaiting Liver Transplantation [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(1): 52-57.
[7]	LUO Kai-yun, WANG Shu-jun, MAO Ping-ping, et al. Comparison of the Efficiency with Different Methods on PRP Preservation and Release of Growth Factors [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(1): 70-73.
[8]	WANG Cui-e, KONG Chang-hong, XU Ye-biao, et al. Establishment and Application of Interval Information Sharing System between Blood Donors and Plasma Donors in Zhejiang Province [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2021, 23(6): 719-722.
[9]	HU Yan, ZHU Bang-qiang, WEN Hui-qin, et al. Lymphoplasmapheresis in ABO-incompatible Living Donor Kidney Transplantation [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2021, 23(5): 608-611.
[10]	YANG Jing, ZHOU Mou, LIN Fang, et al. The Hemostatic and Healing Effect of PRP Chitosan-gelatin Composite Dressing：A Preliminary Evaluation [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2021, 23(5): 612-616.
[11]	YANG Xiao-ya, GAO Yu-hua, LIU Su-rui, et al. Effect of Frozen Storage Platelet-rich Plasma on Inflammatory Response of IL-1β-I Induced Chondrocyte [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2021, 23(4): 442-445.
[12]	CAI Meng-jie, MEI Ren, DAI Lan, et al. The Immunophenotype Characteristics and Clinical Significance of Circulating Tumor Plasma Cell （CTPC） in Multiple Myeloma [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2021, 23(4): 478-482.
[13]	LIN Fang, ZHOU Mou, SHAN Gui-qiu, et al. Comparison of the Effect of Rehydration Solutions Prepared in Different Ingredients on Freeze-dried Platelet-rich Plasma Activation and Release of Growth Factors [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2021, 23(2): 142-145.
[14]	ZHANG Yuan-yuan, YING Mei-ai, PAN Jian, et al. The Clinical Effect of Plasma Exchange in ABO Incompatible Relatives in vivo Kidney Transplantation [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2021, 23(2): 167-172.
[15]	TANG Zong-sheng. Strategies to Enhance the Care and Privacy of Plasma Donors during COVID-19 Rehabilitation and Their Significance [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2020, 22(5): 458-461.